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Antepartum Evaluation ofthe High-Risk Fetus:
Problems and Prospects
by S. Fabro*
The chief obstetrical problems encountered today in the prenatal evaluation of the high-risk
fetus are presented.
Advantages and pitfalls of recent techniques utilized in the management of the high-risk preg-
nancy are discussed. They include: a prenatal scoring system for identifying the high-risk
population; examination of the karyotype of cells in amniotic fluid, and quantitation of
a-fetoprotein levels in maternal plasma and amniotic fluid for the early prenatal detection ofbirth
defects; ultrasonography forthe intrauterine diagnosis offetal growth retardation and assessment
of fetal maturity; the use of maternal urinary estriol excretion, maternal plasma human placental
lactogen levels and the oxytocin stress test for the early detection of fetal distress; estimation of
fetal maturity by amniotic fluid analysis of lecithin or lecithin-sphingomyelin ratios, creatinine
and Blue Nile fetal cell staining.
Newer, still experimental, techniques le.g., fetal breathing movements, fetoscopy, and dehydro-
epiandrosterone plasma clearance) are viewed in light of further possible decreases in maternal
and perinatal mortality.
Maternal mortality in the U.S. showed a dra-
matic decrease, approximately 10-fold, between
1930 and 1960. This decrease has made it possible
to sharpen our focus on the developing fetus,
since over the same period of time, and with the
same high standards of medical care, fetal death
and infant mortality has declined much less
dramatically (1).
One of the reasons for the lack ofimprovement
in neonatal survival is probably that- the human
being in utero is relatively inaccessible to phys-
iologic and/or biochemical measurements. Thus,
our knowledge about the intrauterine develop-
ment of the human conceptus is scanty and in-
direct; it is mainly derived from animal exper-
iments or from retrospective analyses of clinical
material.
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By the latter method it has been possible to
identify the prenatal factors which are most like-
ly to be associated with poor fetal outcome. These
factors include a history of medical or obstetrical
problems, low socioeconomic status, and the de-
velopment of medical complications during the
gestational period (2). Quantitative methods of
scoring a pregnancy for its potential high risk are
currently gaining acceptance. The clinical utility
of a numerical scoring system is validated by the
fact that pregnancies with high prenatal risk
scores are associated with increased perinatal
mortality and morbidity (3,4).
In evaluating the risk encountered with each
pregnancy, obstetricians try to answer the fol-
lowing five questions: (1) Is the fetus malformed?
(2) Is the fetus growing normally? (3) Is the fetus
in distress? (4) How much "reserve" does the fe-
tus have? and (5) Is the fetus capable of ex-
trauterine life?
Congenital malformations occur in 3-4% of
births, and they are responsible for nearly 15% of
all infant mortality (5).
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trician to determine whether a fetus was mal-
formed, and the diagnosis a congenital anomaly
was usually made at birth. The first break-
through in the prenatal diagnosis of congenital
malformations came in 1954, when Steele and
Breg showed that fetuses with chromosomal de-
fects can be identified in high-risk patients by
culturing and karyotyping fetal cells obtained by
amniocentesis (6). For this purpose, amnio-
centesis is carried out early in pregnancy, at
14-16 weeks of gestation, in patients who are
suspected of carrying a fetus with chromosomal
aberrations. If the fetus is found to have a
significantly abnormal karyotype, interruption of
pregnancy can be performed before the fetus at-
tains viability. The early prenatal diagnosis of
genetically determined errors of metabolism,
e.g., Tay-Sachs disease, Niemann-Pick disease,
has also become possible.
Table 1 shows a summary of 800 consecutive
cases for which prenatal chromosome analysis
was requested (7). Maternal age of 35 years or
older, and a previous child with Down's syndrome
were the two most common reasons for perform-
ing amniocentesis. Of the 800 fetuses, 27 (3.4%)
possessed genetic defects, an incidence approx-
imately 6-7 times that in the general population.
The outcome of pregnancy in 648 of these cases
was as follows: therapeutic abortion of 18 of the
fetuses with chromosomal aberrations was per-
formed; five patients terminated their pregnan-
cies by voluntary abortion; 22 aborted spon-
taneously; and there were 6 stillbirths. However,
Table 1. Analysis of consecutive experience with 800 cases
for prenatal genetic diagnosis."
"Affected"
Indication for amniocentesis No. fetuses
Translocation carrier 11 3b
Maternal age 35-39 218 2c
Maternal age 40 + 195 5d
Previous Down's syndrome 120 0
Family history ofDown's syndrome 48 lb
Previous neural tube defect 35 0
Miscellaneous 116 1'
X-Linked disorders 16 8
Metabolic disorders 41 7'
a Data ofMilunsky (7).
bUnbalanced D/G translocation (3).
c 47,XXY (2).
dTrisomy 18 (2), trisomy 21 (2), mosaicism 46,XY/47,XXY
(1).
' Chromosomal breakage, ring chromosome (1).
' Tay-Sachs (3), Hunter's (1), Niemann-Pick (1); 47,XXY (2).
among the 597 live births in this series of pa-
tients, 15 (2.5%/) were abnormal. The type of mal-
formations observed were: Down's syndrome,
Klinefelter's syndrome, craniosynostosis, hydro-
cephaly, myelomeningocoele, cleft lip (two cases),
phocomelia, claw deformity, Tetralogy of Fallot,
hypospadias (two cases), cystic fibrosis, adreno-
genital syndrome, multiple anomalies.
Chromosomal abnormalities had been detected
prenatally in the two cases with Down's and
Klinefelter's syndrome, but the pregnancies were
not terminated. The congenital malformations in
the remaining 13 cases were not associated with
chromosomal aberrations, and therefore could
not be detected by chromosomal analysis.
With the recent observation that alpha-feto-
protein is significantly increased in the amniotic
fluid of fetuses with anencephaly or spina bifida,
the prenatal diagnosis of another group of rather
frequently occurring congenital abnormalities
became possible (8,9).
More recently (10), it has been shown that
a-fetoprotein levels are also elevated in the
serum of women 18-20 weeks pregnant who are
carrying fetuses with spina bifida. This finding
raises the possibility of detecting such nervous
system defects by screening the pregnant popula-
tion early in gestation.
However, the correlation between increases in
the levels of a-fetoprotein and neural closure
defects requires further investigation, since
other conditions, including hydrocephaly (11),
esophageal atresia (12), congenital nephrosis (13),
threatened abortion (14), twin pregnancy (15),
and fetal death (16) are also associated with
elevated alpha-fetoprotein levels in amniotic
fluid. The incidence of false positives and of false
negatives must yet be defined, as must the op-
timal time during gestation for sampling amniotic
fluid. Nevertheless, the potential promise of this
approach is such that large-scale studies are
clearly indicated.
The second problem of the obstetrician is to
establish whether the fetus is growing normally.
It is well known that two conceptuses developing
in the same uterus for the same length oftime (as
in the case of twin pregnancies) may have
different growth rates. Such situations have
forced the perinatologist to define more precisely
the relationship between birth weight and gesta-
tional age. As far as gestational age is concerned,
newborn infants between 38 and 42 weeks of
gestation are categorized as term infants; those
less than 38 weeks are considered preterms, and
post-term infants are those remaining in utero
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also be categorized into three groups as far as
birth weight is concerned: the appropriate for
gestational age (AGA) are newborns whose
weights fall between the 10th and 90th percentile
for the normal mean growth curve; those above
the 90th percentile are called "large for gesta-
tional age" (LGA); and those below the 10th
percentile, the "small for gestational age" (SGA).
This classification has been shown to have great
prognostic value in predicting neonatal mortality.
Thus, a greater incidence of mortality is found
not only in infants at earlier gestational ages, but
also in those infants born too small, or large, for
gestational age ( 7).
Similarly, the IQ scores and the incidence of
central nervous system handicaps in children ap-
pear to be affected by birth weight and gesta-
tional age. Thus, epilepsy, mental retardation,
and cerebral palsy occurred more frequently in
8-year old children who were born prematurely or
had been small for gestational age (18).
The obstetrician must evaluate the growth of
the fetus in utero, but he is limited by the necessi-
ty of using noninvasive techniques for this eval-
uation. For the clinical estimation of gestational
age, five parameters are avilable: length of
amenorrhea, size of the uterus, estimated fetal
body weight, "quickening," and auscultation of
fetal heart by stethoscope. All of these parame-
ters are notoriously inaccurate, and it was for-
tunate for the obstetrician that ultrasound scan-
ning was introduced in clinical practice. This
technique has proved invaluable not only for es-
timating gestational age, but also for monitoring
fetal growth in utero. Thus, it has been shown
that the biparietal diameter of the fetus is pro-
portional to gestational age (19) and that the fetal
biparietal diameter increases at approximately 3
mm per week from the 16th to 32nd week, after
which the growth curve decreases to about 1.8
mm/week. Detection of a decrease in the growth
rate of the biparietal diameter suggests that a
cranial aberration is present. A reduced growth
rate of the biparietal diameter has also been
utilized for diagnosing intrauterine growth retar-
dation (19). Unfortunately, this is a very insen-
sitive method for the latter purpose, since only
those infants suffering from the most severe in-
trauterine growth retardation show a decrease in
the rate of growth of the skull. In the intra-
uterine-retarded fetus, one of the earliest mani-
festations is a decrease in the diameter of the
chest followed by a decrease in its body length,
and then a decreased growth rate of the skull. At
the presnt time, a number of investigators are
trying to develop reliable ultrasound techniques
to measure the size of the fetal trunk, since a
decrease in its rate of growth would provide a
more sensitive method of detecting early intra-
uterine growth retardation (20).
However, the obstetrician must make other
measurements in order to evaluate whether the
fetus is in distress. One such measurement is the
rate of excretion of estriol in the maternal urine.
Because of the relative deficiency of 3-p-hydroxy
steroid dehydrogenase in the fetal adrenals, 16-
hydroxydehydroepiandrosterone sulfate is the
primary compound which crosses from the fetus
to the placenta. The compound is transformed by
placental enzymes into estriol, which then enters
the maternal circulation and is excreted in the
urine, mainly as a glucuronide (21).
According to Beischer et al. (22), the mean
value of urinary estriol excretion is 24 mg/24 hr,
but with a large variability. Thus, values between
40 and 12 mg/24 hr are still considered normal at
term.
A low urinary estriol excretion pattern has
been associated with intrauterine growth retar-
dation, whereas a consistently decreasing uri-
nary estriol excretion rate has been associated
with fetal distress (23).
There is, however, some disagreement as to
the precise urinary estriol level at which fetal
distress is indicated (24). Some workers consider
it to be 1-3 mg in 24-hr urine, others 10-12 mg in
24-hr urine. In addition, the methodology is
tricky and time-consuming, so that results some-
times may not be sufficiently accurate and/or re-
cent to help the obstetrician in the clinical
management of the patient. Numerous other
conditions besides fetal distress are associated
with low urinary estriol values (Table 2), which
further confound the issue (21).
In order to develop better techniques for the
early detection of fetal distress, several methods
have so far been proposed (Table 3).
Some, such as detecting an increased rate of
fetal swallowing by amniography have already
been discarded. Others, such as detecting de-
creased fetal body and respiratory movements by
electronic or ultrasound equipment, appear very
promising. The diagnostic value of abnormalities
in the fetal electrocardiogram is also being
eveluated in the effort to develop a method for
detecting fetal distress. It is hoped that one of
these techniques, or a combination of them, will
prove useful in diagnosing fetal distress more
readily and accurately than is possible now with
the methods presently available.
In managing high-risk pregnancies it is often
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Table 3. Physiological changes indicative offetal distress.
Fetal changes Method Reference
Increased rate of swallowing Amniography (25,26)




sounds FHR changes (29)
Temperature changes
(<1.20F) Thermistors (30)
Prolonged Q-S interval EKG (31)
Shortened pre-ejection
period EKG (32)
No FHR changes after
atropine Fetal monitor (33)
a Q-Ao interval; in sheep.
important to test whether the fetus has a suffi-
cient "reserve" of energy so that it can tolerate
physiological stresses. One such test is the stress
test or oxytocin challenge test, since the stress is
oxytocin-induced uterine contractions.
The main indications for the stress test are
high-risk pregnancies which are likely to be asso-
ciated with poor placental and/or fetal condi-
tions, and include diabetes, toxemia, chronic
hypertension, and intrauterine growth retarda-
tion. Performed on an out-patient basis, the preg-
nant patient is placed in the semisupine position
and abdominal transducers for the detection of
uterine contractions as well as fetal heart rate
are applied. The tocotransducer will make a rec-
ord of the uterine contractions and the ultrasonic
transducer willdetect the fetalheart ratepattern.
After recording a baseline value for 10 min, uter-
ine contractions are produced by an intravenous
oxytocin infusion, at increasing doses, until an
adequate uterine contraction pattern with the
frequency of 3 in 10 min is established. Uterine
contractions result in compression of myometrial
vessels and thereby cause a transient hypoxia in
the fetus. If the fetus has a "good" reserve, no
changes in its fetal heart rate pattern are seen.
The test is said to be negative, and assumes a
good, healthy fetus. If the fetus and/or the
placenta are partially compromised, the transient
hypoxia will be followed by late deceleration of
the fetal heart which is indicative of uterine-
placental insufficiency (34).
It has also been proposed that a human placen-
tal lactogen level of less than 4 ,ug/ml in the
maternal serum at 30-42 weeks of gestation is a
sign of placental insufficiency, and that such a
level correlates reasonably well with immediate
fetal danger (35,36). However, other findings
have confused this issue. For example, human
placental lactogen is decreased in threatened
abortion and is elevated in a twin pregnancy. In
cases of high-risk pregnancy, such as toxemia,
various authors have reported normal levels (37),
low levels (38), and elevated levels (39) of human
placental lactogen. Because of these discrepan-
cies, other placental function tests have recently
been proposed.
They include intervillous blood flow measure-
ments (40), DHEA-S placental clearance (41), pla-
cental biopsy (42), and radioactive selenomethio-
nine uptake by the placenta (43). These tests are
all being evaluated, but some, like placental biop-
sy, appear too invasive to be used clinically;
others, like radioactive selenomethionine uptake,
are probably too toxic to be useful.
At the present time, then, the oxytocin chal-
lenge test appears to be the most practical way to
assess placental function. Although its clinical
significance has to be more clearly defined, the
method is not invasive and is easy to perform on
an ambulatory basis.
The last and probably most important question
that the obstetrician has to answer is: Is this
fetus mature? Is it capable of extrauterine life? It
has been noted above that any time spontaneous
or induced premature labor results in a newborn
which weighs less than 2500 g, there is not only
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probability ofreduced IQ and various central ner-
vous system handicaps. It is remarkable that the
cause(s) of premature labor is (are) at the present
time unknown. Some of the factors associated
with premature labor have been defined, but in
about 50% of the cases the etiology is unknown.
In addition, there are several pathological condi-
tions which force the obstetrician to induce pre-
mature labor, the most common of which is pre-
mature rupture ofthe membranes. This condition
accounts for nearly 60% of all the cases of spon-
taneous and induced premature labor. Neverthe-
less, little, if anything, is known of the etiology of
premature rupture of the membranes. In cases
where early induction of labor is elective, such as
in diabetes or Rh disease, it is essential to
evaluate the capability of the fetus to withstand
extra-uterine life prior to rupturing the mem-
branes. Fetal maturity in an obstetrical sense
was once considered to be a function of gesta-
tional age and the estimated fetal weight, but the
unreliability of these two parameters has already
been discussed. A number of techniques in addi-
tion to clinical methods have been devised to im-
prove our ability to predict fetal maturity.
With the introduction of amniocentesis, it has
been possible to examine the relationship be-
tween fetal maturity and concentration of various
endogenous substances in the amniotic fluid.
Thus, researchers have tried to establish a rela-
tionship between fetal maturity and osmolality
(44), bilirubin concentration (45), creatinine con-
centration (46), or the number of fat cells present
in amniotic fluid (47). However, with the discov-
ery by Gluck (48) that an increased lecithin level
in the amniotic fluid is a sign of lung maturity, a
new approach to this problem was possible. Sub-
sequent studies have shown that the increased
concentration of lecithin in the amniotic fluid
reflects the secretion of surfactant by alveolar
cells. Gluck found that a lecithin/sphingomyelin
(L/S) ratio of 2 or greater is associated with lung
maturity. In a normal human pregnancy this ratio
is attained at about 35 weeks of gestation; there
is accumulating evidence which suggests that
some high-risk prenatal conditions might accel-
erate or delay the maturation of the L/S ratio.
Accelerated maturation occurs in association
with both maternal conditions (e.g., toxemia and
hypertension) and placental disease (e.g., cir-
cumvallate placenta or placental insufficiency).
According to Gluck, premature rupture of the
membranes more than 24 hr before delivery
causes acceleration in the maturation of the L/S
ratio (48), although this has been refuted recently
by a group of workers in Colorado (49).
Delayed maturation of the L/S ratio may be
found in the smaller of chorionic twins as well as
in Class A, B and C diabetes, chronic glomerulo-
nephritis, and hydrops fetalis (48). There is an in-
verse relationship between the L/S ratio and the
number of deaths from hyaline membrane dis-
ease. ihus, only 0.3% of the patients with L/S
ratios equal to or greater than 2 had an offspring
that died of hyaline membrane disease, and this
incidence increases with decreasing L/S ratios
(50).
In summary, we have evaluated the most com-
mon and important obstetrical problems of the
modern obstetrician. Our attitude toward the
welfare of the patient has changed somewhat in
recent years, and particularly changed is our ap-
proach to the fetus. In the past the fetus was not
asked anything. Today in evaluating any high-
risk pregnancy we have learned constantly to ask
the fetus, "How well are you doing?" and, "Would
you prefer to be somew-here else?" (51).
There is no doubt that improvements in our
techniques will make the fetus more accessible to
biochemical and physiological measurement. It is
hoped that these technological advances will not
only lead to decreases in perinatal mortality, but
also will improve the overall quality of life of our
offspring.
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